Syndax_JPM 2025_FINAL_.pdf

1、Syndax Corporate Presentation43rdAnnual J.P.Morgan Healthcare ConferenceJanuary 14,2025Forward-looking statements disclosureThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.Words such asmay,will,expect,plan,anticipate an

2、d similar expressions(as well as other words or expressions referencing future events,progress,timing or circumstances)are intended to identify forward-looking statements.All statements other than statements of historical facts containedin this presentation,including statements regarding future oper

3、ations,financial results and the financial condition of Syndax Pharmaceuticals,Inc.(“Syndax”or the“Company”),including financial position,strategy and plans,the progress,timing,clinical development and scope ofclinical trials and the reporting of clinical data for Syndaxs product candidates,the prog

4、ress of regulatory submissions and approvals andsubsequent commercialization and the potential use of Syndaxs product candidates to treat various cancer indications and fibrotic diseases,andSyndaxs expectations for liquidity and future operations,are forward-looking statements.Many factors may cause

5、 differences between currentexpectations and actual results,including unexpected safety or efficacy data observed during preclinical studies or clinical trials,clinical siteactivation rates or clinical trial enrollment rates that are lower than expected;changes in expected or existing competition;th

6、e impact ofmacroeconomic conditions(the Russia-Ukraine war,inflation,among others)on Syndaxs business and that of the third parties on which Syndaxdepends,including delaying or otherwise disrupting Syndaxs clinical trials and preclinical studies,manufacturing and supply chain,or impairingemployee pr